USD 9.28
(33.91%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 224.41 Million USD | -2.52% |
2022 | 230.23 Million USD | 246.56% |
2021 | 66.43 Million USD | -60.46% |
2020 | 167.99 Million USD | -1.65% |
2019 | 170.81 Million USD | 11.41% |
2018 | 153.31 Million USD | -0.92% |
2017 | 154.74 Million USD | 28.81% |
2016 | 120.14 Million USD | 94.08% |
2015 | 61.9 Million USD | 613.64% |
2014 | 8.67 Million USD | 28.69% |
2013 | 6.74 Million USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 206.77 Million USD | 0.0% |
2024 Q2 | 194.19 Million USD | 0.0% |
2023 Q4 | 224.41 Million USD | -3.28% |
2023 Q3 | 232.02 Million USD | -3.03% |
2023 Q2 | 239.26 Million USD | 7.79% |
2023 Q1 | 221.97 Million USD | -3.59% |
2023 FY | 224.41 Million USD | -2.52% |
2022 Q4 | 230.23 Million USD | -1.79% |
2022 Q2 | 244.52 Million USD | 188.26% |
2022 Q1 | 84.82 Million USD | 27.69% |
2022 FY | 230.23 Million USD | 246.56% |
2022 Q3 | 234.42 Million USD | -4.13% |
2021 Q1 | 177.7 Million USD | 5.78% |
2021 Q2 | 169.93 Million USD | -4.37% |
2021 FY | 66.43 Million USD | -60.46% |
2021 Q3 | 152.12 Million USD | -10.48% |
2021 Q4 | 66.43 Million USD | -56.33% |
2020 Q4 | 167.99 Million USD | -2.93% |
2020 Q3 | 173.07 Million USD | -0.85% |
2020 Q1 | 179.96 Million USD | 5.36% |
2020 Q2 | 174.56 Million USD | -3.0% |
2020 FY | 167.99 Million USD | -1.65% |
2019 Q2 | 175.35 Million USD | 4.25% |
2019 FY | 170.81 Million USD | 11.41% |
2019 Q4 | 170.81 Million USD | -2.96% |
2019 Q3 | 176.02 Million USD | 0.39% |
2019 Q1 | 168.2 Million USD | 9.71% |
2018 Q1 | 154.54 Million USD | -0.13% |
2018 FY | 153.31 Million USD | -0.92% |
2018 Q4 | 153.31 Million USD | -0.26% |
2018 Q3 | 153.71 Million USD | -0.25% |
2018 Q2 | 154.1 Million USD | -0.29% |
2017 Q1 | 147.55 Million USD | 22.82% |
2017 Q2 | 153.96 Million USD | 4.34% |
2017 FY | 154.74 Million USD | 28.81% |
2017 Q4 | 154.74 Million USD | 0.33% |
2017 Q3 | 154.24 Million USD | 0.18% |
2016 Q3 | 99.99 Million USD | 15.43% |
2016 Q4 | 120.14 Million USD | 20.15% |
2016 Q1 | 74.41 Million USD | 20.21% |
2016 Q2 | 86.62 Million USD | 16.41% |
2016 FY | 120.14 Million USD | 94.08% |
2015 Q2 | 8.22 Million USD | 0.0% |
2015 Q3 | 43.77 Million USD | 432.37% |
2015 Q4 | 61.9 Million USD | 41.4% |
2015 Q1 | - USD | -100.0% |
2015 FY | 61.9 Million USD | 613.64% |
2014 Q3 | 8.72 Million USD | 8.29% |
2014 Q1 | 7.26 Million USD | 7.76% |
2014 Q4 | 8.67 Million USD | -0.57% |
2014 Q2 | 8.05 Million USD | 10.92% |
2014 FY | 8.67 Million USD | 28.69% |
2013 Q2 | - USD | 0.0% |
2013 FY | 6.74 Million USD | 0.0% |
2013 Q4 | 6.74 Million USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Editas Medicine, Inc. | 24.37 Million USD | -820.807% |
Dynavax Technologies Corporation | 252.41 Million USD | 11.092% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -576.042% |
Perrigo Company plc | 3.63 Billion USD | 93.822% |
Illumina, Inc. | 1.48 Billion USD | 84.928% |
Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.283% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -22341.9% |
Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 97.21% |
IQVIA Holdings Inc. | 12.95 Billion USD | 98.268% |
Heron Therapeutics, Inc. | 173.75 Million USD | -29.16% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 91.697% |
Unity Biotechnology, Inc. | 23.53 Million USD | -853.392% |
Waters Corporation | 2.3 Billion USD | 90.266% |
Biogen Inc. | 7.18 Billion USD | 96.878% |
Sangamo Therapeutics, Inc. | 33.51 Million USD | -569.608% |
Evolus, Inc. | 120.35 Million USD | -86.458% |
Adicet Bio, Inc. | 17.7 Million USD | -1167.689% |
Cara Therapeutics, Inc. | 37.07 Million USD | -505.246% |
Esperion Therapeutics, Inc. | 501.54 Million USD | 55.255% |
FibroGen, Inc. | 89.69 Million USD | -150.197% |
Agilent Technologies, Inc. | 2.73 Billion USD | 91.795% |
Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -6829.44% |
Homology Medicines, Inc. | 43.17 Million USD | -419.777% |
Geron Corporation | 35.05 Million USD | -540.264% |
Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 90.422% |
Amicus Therapeutics, Inc. | 387.85 Million USD | 42.139% |
Myriad Genetics, Inc. | 130.9 Million USD | -71.443% |
Viking Therapeutics, Inc. | 936 Thousand USD | -23876.389% |
Intellia Therapeutics, Inc. | 96.74 Million USD | -131.965% |
Zoetis Inc. | 6.56 Billion USD | 96.581% |
Abeona Therapeutics Inc. | 4.4 Million USD | -4998.114% |
Mettler-Toledo International Inc. | 1.97 Billion USD | 88.64% |
BioMarin Pharmaceutical Inc. | 593.09 Million USD | 62.161% |
Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 69.033% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | -556.388% |
Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 83.974% |
Atara Biotherapeutics, Inc. | 45.69 Million USD | -391.145% |
Verastem, Inc. | 40.08 Million USD | -459.844% |
Nektar Therapeutics | 112.62 Million USD | -99.262% |
Axsome Therapeutics, Inc. | 178.07 Million USD | -26.029% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -7200.553% |
Sarepta Therapeutics, Inc. | 1.13 Billion USD | 80.184% |
OPKO Health, Inc. | 222.03 Million USD | -1.074% |
Exelixis, Inc. | 189.94 Million USD | -18.15% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | 13.117% |
Corcept Therapeutics Incorporated | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 130.06 Million USD | -72.544% |
Imunon, Inc. | 1.13 Million USD | -19598.093% |
Blueprint Medicines Corporation | 610.96 Million USD | 63.268% |
Insmed Incorporated | 1.19 Billion USD | 81.194% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 85.031% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -293.8% |
TG Therapeutics, Inc. | 100.11 Million USD | -124.154% |
Incyte Corporation | 29.16 Million USD | -669.56% |
Emergent BioSolutions Inc. | 446.5 Million USD | 49.738% |